HC Wainwright Reaffirms “Buy” Rating for TuHURA Biosciences (NASDAQ:HURA)

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 206.12% from the company’s previous close. HC Wainwright also issued estimates for TuHURA Biosciences’ FY2025 earnings at ($0.56) EPS and FY2026 earnings at ($0.52) EPS.

TuHURA Biosciences Stock Up 2.1%

Shares of NASDAQ HURA opened at $3.92 on Friday. The company has a 50 day simple moving average of $3.68 and a two-hundred day simple moving average of $4.07. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Institutional Trading of TuHURA Biosciences

Hedge funds have recently made changes to their positions in the business. Accent Capital Management LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $29,000. TT Capital Management LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $41,000. Jefferies Financial Group Inc. purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $54,000. Bank of America Corp DE bought a new position in TuHURA Biosciences during the 4th quarter valued at about $59,000. Finally, Charles Schwab Investment Management Inc. bought a new position in TuHURA Biosciences during the 4th quarter valued at about $61,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.